Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Leerink Swann lifted their FY2017 earnings per share estimates for shares of Gilead Sciences in a research report issued to clients and investors on Thursday, Zacks Investment Research reports. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will post earnings of $8.82 per share for the year, up from their prior estimate of $8.37. Leerink Swann has a “Market Perform” rating and a $83.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q4 2018 earnings at $1.72 EPS and FY2019 earnings at $6.84 EPS.
Other research analysts have also issued reports about the company. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective for the company in a research report on Monday, February 5th. Mizuho reissued a “buy” rating and issued a $95.00 price objective (up from $83.00) on shares of Gilead Sciences in a research report on Monday. Citigroup reaffirmed a “buy” rating and issued a $105.00 target price (up from $103.00) on shares of Gilead Sciences in a research report on Thursday. BMO Capital Markets boosted their target price on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research report on Thursday. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $87.04.
Gilead Sciences (NASDAQ:GILD) traded up $0.82 during mid-day trading on Friday, hitting $80.14. The stock had a trading volume of 9,972,034 shares, compared to its average volume of 9,910,000. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. The company has a market cap of $104,660.00, a price-to-earnings ratio of 23.03, a PEG ratio of -1.77 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the company posted $2.70 EPS. The business’s quarterly revenue was down 18.7% on a year-over-year basis.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is presently 59.77%.
In other news, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the transaction, the executive vice president now owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 358,333 shares of company stock worth $28,066,908 in the last 90 days. Company insiders own 1.30% of the company’s stock.
A number of institutional investors have recently bought and sold shares of GILD. Capital International Investors lifted its stake in Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after purchasing an additional 5,205,983 shares during the last quarter. Sanders Capital LLC lifted its stake in Gilead Sciences by 102.9% in the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after purchasing an additional 5,026,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its stake in Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after purchasing an additional 3,434,450 shares during the last quarter. CI Global Investments Inc. lifted its stake in Gilead Sciences by 5,461.1% in the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after purchasing an additional 3,257,969 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Gilead Sciences by 12,545.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,070,327 shares of the biopharmaceutical company’s stock valued at $219,958,000 after purchasing an additional 3,046,047 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Leerink Swann Comments on Gilead Sciences, Inc.’s FY2017 Earnings (NASDAQ:GILD)” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/12/leerink-swann-weighs-in-on-gilead-sciences-inc-s-fy2017-earnings-gild-updated-updated-updated.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.